|
1
|
Ansari J, Naqash AR, Munker R, El-Osta H,
Master S, Cotelingam JD, Griffiths E, Greer AH, Yin H, Peddi P and
Shackelford RE: Histiocytic sarcoma as a secondary malignancy:
Pathobiology, diagnosis, and treatment. Eur J Haematol. 97:9–16.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hung YP and Qian X: Histiocytic sarcoma.
Arch Pathol Lab Med. 144:650–654. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Egan C, Lack J, Skarshaug S, Pham TA,
Abdullaev Z, Xi L, Pack S, Pittaluga S, Jaffe ES and Raffeld M: The
mutational landscape of histiocytic sarcoma associated with
lymphoid malignancy. Mod Pathol. 34:336–347. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Butrynski JE, D'Adamo DR, Hornick JL, Dal
Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ,
Ramaiya N, et al: Crizotinib in ALK-rearranged inflammatory
myofibroblastic tumor. N Engl J Med. 363:1727–1733. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gambacorti-Passerini C, Orlov S, Zhang L,
Braiteh F, Huang H, Esaki T, Horibe K, Ahn JS, Beck JT, Edenfield
WJ, et al: Long-term effects of crizotinib in ALK-positive tumors
(excluding NSCLC): A phase 1b open-label study. Am J Hematol.
93:607–614. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
International Agency for Research on
Cancer (IARC), . Soft tissue and bone tumours. Vol 3. IARC; Lyon,
France: 2020
|
|
7
|
Sethi B, Pai T, Allam A and Epari S:
Anaplastic lymphoma kinase-positive pulmonary inflammatory
myofibroblastic tumor with sarcomatous morphology and distant
metastases: An unusual histomorphology and behavior. Indian J
Pathol Microbiol. 58:509–512. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang L and Wang W: Safety and efficacy of
anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small
cell lung cancer (Review). Oncol Rep. 45:13–28. 2021.PubMed/NCBI
|
|
9
|
Zou Z, Xing P, Hao X, Wang Y, Song X, Shan
L, Zhang C, Liu Z, Ma K, Dong G and Li J: Intracranial efficacy of
alectinib in ALK-positive NSCLC patients with CNS metastases-a
multicenter retrospective study. BMC Med. 20:122022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
WHO, . Classification of tumours editorial
board. Soft tissue and bone tumours. Lyon (France): International
agency for research on cancer. Journal. 3:1042020.
|
|
11
|
Go RS, Jacobsen E, Baiocchi R, Buhtoiarov
I, Butler EB, Campbell PK, Coulter DW, Diamond E, Flagg A, Goodman
AM, et al: Histiocytic neoplasms, version 2.2021, NCCN clinical
practice guidelines in oncology. J Natl Compr Cancer Netw.
19:1277–1303. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H and Thiele J: WHO classification of tumours of
haematopoietic and lymphoid tissues. International agency for
research on cancer Lyon; 2008
|
|
13
|
Picarsic J and Jaffe R: Pathology of
histiocytic disorders and neoplasms and related disorders.
Histiocytic disorders. Abla O and Janka G: Springer International
Publishing; Cham: pp. 3–50. 2018, View Article : Google Scholar
|
|
14
|
Yogarajah M and Tefferi A: Leukemic
transformation in myeloproliferative neoplasms: A literature review
on risk, characteristics, and outcome. Mayo Clin Proc.
92:1118–1128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kemps PG, Picarsic J, Durham BH,
Hélias-Rodzewicz Z, Hiemcke-Jiwa L, van den Bos C, van de Wetering
MD, van Noesel CJM, van Laar JAM, Verdijk RM, et al: ALK-positive
histiocytosis: A new clinicopathologic spectrum highlighting
neurologic involvement and responses to ALK inhibition. Blood.
139:256–280. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reddivari AKR, Mehta P and Janapala US:
Rare presentation of a rare tumor: Histiocytic sarcoma. Cureus.
12:e77702020.PubMed/NCBI
|
|
17
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu X, Li H, Peng K, Yu Y, Chen L, Fang Y,
Sun Y, Hou Y and Liu T: ALK-G1269A mutation in epithelioid
inflammatory myofibroblastic sarcoma after progression on
crizotinib: A case report. Oncol Lett. 17:2370–2376.
2019.PubMed/NCBI
|
|
19
|
Shon W and Billings SD: Epithelioid
vascular tumors: A review. Adv Anat Pathol. 26:186–197. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luzar B and Calonje E: Update on cutaneous
epithelioid vascular tumours. Diagnostic Histopathology.
24:273–287. 2018. View Article : Google Scholar
|
|
21
|
Folpe AL: Vascular tumors of intermediate
malignancy: An update. Hum Pathol. 147:114–128. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Magdy M, Karim NA, Eldessouki I, Gaber O,
Rahouma M and Ghareeb M: Myeloid sarcoma. Oncol Res Treat.
42:224–229. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thalhammer-Scherrer R, Mitterbauer G,
Simonitsch I, Jaeger U, Lechner K, Schneider B, Fonatsch C and
Schwarzinger I: The immunophenotype of 325 adult acute leukemias:
Relationship to morphologic and molecular classification and
proposal for a minimal screening program highly predictive for
lineage discrimination. Am J Clin Pathol. 117:380–389. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xue T, Jiang XN, Wang WG, Zhou XY and Li
XQ: Interdigitating dendritic cell sarcoma: Clinicopathologic study
of 8 cases with review of the literature. Ann Diagn Pathol.
34:155–160. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Szumera-Ciećkiewicz A, Bosisio F, Teterycz
P, Antoranz A, Delogu F, Koljenović S, van de Wiel BA, Blokx W, van
Kempen LC, Rutkowski P, et al: SOX10 is as specific as S100 protein
in detecting metastases of melanoma in lymph nodes and is
recommended for sentinel lymph node assessment. Eur J Cancer.
137:175–182. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tuffaha MSA, Guski H and Kristiansen G:
Markers and immunoprofile of lymphoid neoplasms.
Immunohistochemistry in tumor diagnostics. Springer International
Publishing; Cham: pp. 207–250. 2023, View Article : Google Scholar
|
|
27
|
Facchetti F, Simbeni M and Lorenzi L:
Follicular dendritic cell sarcoma. Pathologica. 113:316–329. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Russo A, Franchina T, Ricciardi GRR,
Ferraro G, Scimone A, Bronte G, Russo A, Rolfo C and Adamo V:
Central nervous system involvement in ALK-rearranged NSCLC:
promising strategies to overcome crizotinib resistance. Expert Rev
Anticancer Ther. 16:615–623. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nelson TA and Wang N: Targeting lung
cancer brain metastases: A narrative review of emerging insights
for anaplastic lymphoma kinase (ALK)-positive disease. Transl Lung
Cancer Res. 12:379–392. 2023. View Article : Google Scholar : PubMed/NCBI
|
